Beyond A1C: Glycated Albumin Takes Center Stage at 2017 AACC Symposium in San Diego
July 31, 2017
The American Association for Clinical Chemistry (AACC) and the American Diabetes Association (ADA) have recognized the need to look beyond HbA1c for biomarkers in diabetes management. They have joined forces and holding a symposium during the 69th AACC Annual Scientific Meeting & Clinical Lab Expo taking place in San Diego July 30-August 3 2017. Symposium will explore supplemental biomarkers “Looking Beyond HbA1c ”. it will be held during AACC meeting on August 1, 2017 at 2:30pm.
Epinex has been at the forefront in advocating a role for Glycated Albumin for early detection, screening and monthly monitoring of diabetes, we are very excited to attend this particular symposium. Epinex had patented a rapid test -G1A- for Glycated Albumin and is developing the test for clinical trials. G1A measures total albumin and glycated albumin exclusively (not fructosamine) in a hand held device as POCT (Point of Care Test)for doctors’ offices and clinics and as a OTC ( Over The Counter) test for general public use.